IL-17 SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES

摘要

The present disclosure relates to a method of selectively reducing CysL97 in a formulation of an IL-17 antibody or an antigen-binding fragment thereof recombinantly produced by a mammalian cell (for example, a preparation of a secukinumab antibody) will be. The level of intact IL-17 antibody or antigen-binding fragment thereof (e.g., succinimin) in the formulation when measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS) is high, for example at least about 90 % And the level of activity of the IL-17 antibody or antigen-binding fragment thereof (e.g., secukinupt) in the preparation is high, for example, at least about 92%, as measured by a cation exchange chromatograph (CEX) Also provided are purified formulations of IL-17 antibodies or antigen-binding fragments thereof produced by such methods, such as, for example, purified formulations of Sicquinimum.